Axa
MRSN

Axa’s Mersana Therapeutics MRSN Stock Holding History

Axa’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,164
Closed -$610K – 1152
2022
Q4 		$610K Sell
4,164
-5,148
-55% -$870K ﹤0.01% 965
2022
Q3 		$1.57M Buy
9,312
+8,880
+2,056% +$1.44M 0.01% 791
2022
Q2 		$49.9K Hold
432
– – ﹤0.01% 1101
2022
Q1 		$43.1K Sell
432
-5,488
-93% -$641K ﹤0.01% 1178
2021
Q4 		$921K Buy
+5,920
New +$1.15M ﹤0.01% 957
2021
Q1 		– Sell
-8,202
Closed -$5.46M – 1289
2020
Q4 		$5.46M Buy
8,202
+331
+4% +$184K 0.02% 671
2020
Q3 		$3.66M Sell
7,871
-2,477
-24% -$1.25M 0.01% 706
2020
Q2 		$6.05M Sell
10,348
-3,991
-28% -$1.36M 0.02% 556
2020
Q1 		$2.09M Buy
+14,339
New +$2.51M 0.01% 725

Other funds holding MRSN

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return